Headline: FDA Approves First-Ever Twice-Yearly HIV Prevention Shot
Caption:
Keywords: Health and Wellbeing,FDA,lenacapavir,Yeztugo,HIV prevention,twice-yearly injection,PrEP,clinical trials,adults,adolescents,HIV risk,daily pill alternative,low-maintenance,stigma,access,forgetfulness,cost,$28,000,Gilead,generic license,low-income countries,global access,game-changer,health equity
PersonInImage: